Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis | Psychological Medicine | Cambridge Core (original) (raw)

References

Basterzi, AD, Aydemir, C, Kisa, C, Aksaray, S, Tuzer, V, Yazici, K, Goka, E (2005). IL-6 levels decrease with SSRI treatment in patients with major depression. Human Psychopharmacology 20, 473–476.CrossRefGoogle ScholarPubMed

Bland, JM, Altman, DG (1994). Statistics notes: some examples of regression towards the mean. British Medical Journal 309, 780.CrossRefGoogle Scholar

Borenstein, M, Hedges, LV, Higgins, JPT, Rothstein, HR (2009). Introduction to Meta-analysis. John Wiley & Sons: Chichester, UK.CrossRefGoogle Scholar

Bossola, M, Ciciarelli, C, Di Stasio, E, Conte, GL, Vulpio, C, Luciani, G, Tazza, L (2010). Correlates of symptoms of depression and anxiety in chronic hemodialysis patients. General Hospital Psychiatry 32, 125–131.CrossRefGoogle ScholarPubMed

Carvalho, LA, Garner, BA, Dew, T, Fazakerley, H, Pariante, CM (2010). Antidepressants, but not antipsychotics, modulate GR function in human whole blood: an insight into molecular mechanisms. European Neuropsychopharmacology 20, 379–387.CrossRefGoogle ScholarPubMed

Carvalho, LA, Pariante, CM (2008). In vitro modulation of the glucocorticoid receptor by antidepressants. Stress: The International Journal on the Biology of Stress 11, 411–424.CrossRefGoogle ScholarPubMed

Chen, Y-C, Lin, W-W, Chen, Y-J, Mao, W-C, Hung, Y-J (2010). Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediators of Inflammation. Published online: 18 May 2010. doi:10.1155/2010/573594.CrossRefGoogle ScholarPubMed

Dawood, T, Lambert, EA, Barton, DA, Laude, D, Elghozi, JL, Esler, MD, Haikerwal, D, Kaye, DM, Hotchkin, EJ, Lambert, GW (2007). Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertension Research 30, 285–293.CrossRefGoogle ScholarPubMed

Dowlati, Y, Herrmann, N, Swardfager, W, Liu, H, Sham, L, Reim, EK, Lanctôt, KL (2010). A meta-analysis of cytokines in major depression. Biological Psychiatry 67, 446–457.CrossRefGoogle ScholarPubMed

Egger, M, Davey Smith, G, Schneider, M, Minder, C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629–634.CrossRefGoogle ScholarPubMed

Evans, DL, Charney, DS, Lewis, L, Golden, RN, Gorman, JM, Krishnan, KRR, Nemeroff, CB, Bremner, JD, Carney, RM, Coyne, JC, Delong, MR, Frasure-Smith, N, Glassman, AH, Gold, PW, Grant, I, Gwyther, L, Ironson, G, Johnson, RL, Kanner, AM, Katon, WJ, Kaufmann, PG, Keefe, FJ, Ketter, T, Laughren, TP, Leserman, J, Lyketsos, CG, McDonald, WM, McEwen, BS, Miller, AH, Musselman, D, O'Connor, C, Petitto, JM, Pollock, BG, Robinson, RG, Roose, SP, Rowland, J, Sheline, Y, Sheps, DS, Simon, G, Spiegel, D, Stunkard, A, Sunderland, T, Tibbits, JP, Valvo, WJ (2005). Mood disorders in the medically ill: scientific review and recommendations. Biological Psychiatry 58, 175–189.CrossRefGoogle Scholar

Fornaro, M, Martino, M, Battaglia, F, Colicchio, S, Perugi, G (2011). Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. Neuropsychiatric Disease and Treatment 7, 51–56.CrossRefGoogle ScholarPubMed

Gabay, C, Kushner, I (1999). Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine 340, 448–454.CrossRefGoogle ScholarPubMed

Hernandez, ME, Mendieta, D, Martinez-Fong, D, Loria, F, Moreno, J, Estrada, I, Bojalil, R, Pavon, L (2008). Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. European Neuropsychopharmacology 18, 917–924.CrossRefGoogle ScholarPubMed

Higgins, JPT, Thompson, SG, Deeks, JJ, Altman, DG (2003). Measuring inconsistency in meta-analyses. British Medical Journal 327, 557–560.CrossRefGoogle ScholarPubMed

Howren, MB, Lamkin, DM, Suls, J (2009). Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 71, 171–186.CrossRefGoogle ScholarPubMed

Irwin, MR, Miller, AH (2007). Depressive disorders and immunity: 20 years of progress and discovery. Brain, Behavior, and Immunity 21, 374–383.CrossRefGoogle ScholarPubMed

Janssen, DGA, Caniato, RN, Verster, JC, Baune, BT (2010). A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Human Psychopharmacology 25, 201–215.CrossRefGoogle ScholarPubMed

Jazayeri, S, Keshavarz, SA, Tehrani-Doost, M, Djalali, M, Hosseini, M, Amini, H, Chamari, M, Djazayery, A (2010). Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Research 178, 112–115.CrossRefGoogle ScholarPubMed

Kagaya, A, Kugaya, A, Takebayashi, M, Fukue-Saeki, M, Saeki, T, Yamawaki, S, Uchitomi, Y (2001). Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 43, 59–62.CrossRefGoogle ScholarPubMed

Kenis, G, Maes, M (2002). Effects of antidepressants on the production of cytokines. International Journal of Neuropsychopharmacology 5, 401–142.CrossRefGoogle ScholarPubMed

Khan, AMD, Brodhead, AEMS, Schwartz, KAMS, Kolts, RLP, Brown, WAMD (2005). Sex differences in antidepressant response in recent antidepressant clinical trials. Journal of Clinical Psychopharmacology 25, 318–324.CrossRefGoogle ScholarPubMed

Kubera, M, Kenis, G, Bosmans, E, Zieba, A, Dudek, D, Nowak, G, Maes, M (2000). Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Polish Journal of Pharmacology 52, 237–241.Google ScholarPubMed

Lanquillon, S, Krieg, JC, Bening-Abu-Shach, U, Vedder, H (2000). Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370–379.CrossRefGoogle ScholarPubMed

Leo, R, Di Lorenzo, G, Tesauro, M, Razzini, C, Forleo, GB, Chiricolo, G, Cola, C, Zanasi, M, Troisi, A, Siracusano, A, Lauro, R, Romeo, F (2006). Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. Journal of Clinical Psychiatry 67, 1760–1766.CrossRefGoogle ScholarPubMed

Lindqvist, D, Janelidze, S, Hagell, P, Erhardt, S, Samuelsson, M, Minthon, L, Hansson, O, Bjorkqvist, M, Traskman-Bendz, L, Brundin, L (2009). Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biological Psychiatry 66, 287–292.CrossRefGoogle ScholarPubMed

Mackay, GM, Forrest, CM, Christofides, J, Bridel, MA, Mitchell, S, Cowlard, R, Stone, TW, Darlington, LG (2009). Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clinical and Experimental Pharmacology and Physiology 36, 425–435.CrossRefGoogle ScholarPubMed

Maes, M (2001). The immunoregulatory effects of antidepressants. Human Psychopharmacology: Clinical and Experimental 16, 95–103.CrossRefGoogle ScholarPubMed

Maes, M, Bosmans, E, De Jongh, R, Kenis, G, Vandoolaeghe, E, Neels, H (1997). Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9, 853–858.CrossRefGoogle ScholarPubMed

Maes, M, Meltzer, HY, Bosmans, E, Bergmans, R, Vandoolaeghe, E, Ranjan, R, Desnyder, R (1995). Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorders 34, 301–309.CrossRefGoogle ScholarPubMed

Maes, M, Yirmyia, R, Noraberg, J, Brene, S, Hibbeln, J, Perini, G, Kubera, M, Bob, P, Lerer, B, Maj, M (2009). The inflammatory and neurodegenerative hypothesis of depression: leads for future research and new drug developments in depression. Metabolic Brain Disease 24, 27–53.CrossRefGoogle ScholarPubMed

Mikova, O, Yakimova, R, Bosmans, E, Kenis, G, Maes, M (2001). Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. European Neuropsychopharmacology 11, 203–208.CrossRefGoogle ScholarPubMed

Miller, AH, Maletic, V, Raison, CL (2009). Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 65, 732–741.CrossRefGoogle ScholarPubMed

Moore, KW, de Waal Malefyt, R, Coffman, RL, O'Garra, A (2001). Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology 19, 683–765.CrossRefGoogle ScholarPubMed

O'Brien, SM, Scott, LV, Dinan, TG (2006). Antidepressant therapy and C-reactive protein levels. British Journal of Psychiatry 188, 449–452.CrossRefGoogle ScholarPubMed

O'Donovan, A, Hughes, BM, Slavich, GM, Lynch, L, Cronin, M-T, O'Farrelly, C, Malone, KM (2010). Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain, Behavior, and Immunity 24, 1074–1077.CrossRefGoogle ScholarPubMed

Park, HS, Park, JY, Yu, R (2005). Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Research and Clinical Practice 69, 29–35.CrossRefGoogle ScholarPubMed

Pizzi, C, Mancini, S, Angeloni, L, Fontana, F, Manzoli, L, Costa, GM (2009). Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology & Therapeutics 86, 527–32.CrossRefGoogle Scholar

Pudar Hozo, S, Djulbegovic, B, Hozo, I (2005). Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 5(13).Google Scholar

Rosenthal, R (1979). The file drawer problem and tolerance for null results. Psychological Bulletin 86, 638–641.CrossRefGoogle Scholar

Rothermundt, M, Arolt, V, Fenker, J, Gutbrodt, H, Peters, M, Kirchner, H (2001). Different immune patterns in melancholic and non-melancholic major depression. European Archives of Psychiatry and Clinical Neuroscience 251, 90–97.CrossRefGoogle ScholarPubMed

Rush, AJ, Zimmerman, M, Wisniewski, SR, Fava, M, Hollon, SD, Warden, D, Biggs, MM, Shores-Wilson, K, Shelton, RC, Luther, JF, Thomas, B, Trivedi, MH (2005). Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. Journal of Affective Disorders 87, 43–55.CrossRefGoogle ScholarPubMed

Serretti, A, Mandelli, L (2010). Antidepressants and body weight: a comprehensive review and meta-analysis. Journal of Clinical Psychiatry 71, 1259–1272.CrossRefGoogle ScholarPubMed

Sluzewska, A, Rybakowski, JK, Laciak, M, Mackiewicz, A, Sobieska, M, Wiktorowicz, K (1995). Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Annals of the New York Academy of Sciences 762, 474–476.CrossRefGoogle ScholarPubMed

Sluzewska, A, Sobieska, M, Rybakowski, JK (1997). Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 35, 123–127.CrossRefGoogle ScholarPubMed

Song, C, Halbreich, U, Han, C, Leonard, BE, Luo, H (2009). Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 42, 182–188.CrossRefGoogle ScholarPubMed

Tuglu, C, Kara, SH, Caliyurt, O, Vardar, E, Abay, E (2003). Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 170, 429–433.CrossRefGoogle ScholarPubMed

Yao, H, Tao, L-G, Zhang, X-B, Sha, W-W, Hou, G, Zhang, Z-J (2004). Variety of cell-mediated immunity and the metabolic products of monoamine neural transmitter in depression patients before and after therapy. Chinese Journal of Clinical Rehabilitation 8, 2978–2979.Google Scholar

Yoshimura, R, Hori, H, Ikenouchi-Sugita, A, Umene-Nakano, W, Ueda, N, Nakamura, J (2009). Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33, 722–726.CrossRefGoogle ScholarPubMed

Zorrilla, EP, Luborsky, L, McKay, JR, Rosenthal, R, Houldin, A, Tax, A, McCorkle, R, Seligman, DA, Schmidt, K (2001). The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain, Behavior and Immunity 15, 199–226.CrossRefGoogle ScholarPubMed